pour la recherche uniquement
Réf. Catalogue: S2662
Structure chimique
| Cibles apparentées | JAK TGF-beta/Smad ERK GSK-3 ROCK Hedgehog/Smoothened PKA Secretase STAT Casein Kinase |
|---|---|
| Autre Wnt/beta-catenin Inhibiteurs | IWR-1-endo PRI-724 (Foscenvivint) IWP-2 Tegatrabetan (BC-2059) Isoquercitrin SKL2001 BML-284 Hydrochloride (Wnt agonist 1, AMBMP) PNU-74654 LF3 Salinomycin (Procoxacin) |
| Lignées cellulaires | Type d'essai | Concentration | Temps d'incubation | Formulation | Description de l'activité | PMID |
|---|---|---|---|---|---|---|
| SH-SY5Y | Apoptosis Assay | 50 μm | 24 h | DMSO | blocks the protective effect of melatonin against PrP (106–126)-induced apoptotic signals | 25251028 |
| AsPC-1 | Growth Inhibition Assay | 1-20 μM | 2/4/6 d | inhibits the cell growth in a dose-dependent manner | 25082960 | |
| MiaPaCa-2 | Growth Inhibition Assay | 1-20 μM | 2/4/6 d | inhibits the cell growth in a dose-dependent manner | 25082960 | |
| PANC-1 | Growth Inhibition Assay | 1-20 μM | 2/4/6 d | inhibits the cell growth in a dose-dependent manner | 25082960 | |
| L3.6pl | Growth Inhibition Assay | 1-20 μM | 2/4/6 d | inhibits the cell growth in a dose-dependent manner | 25082960 | |
| SH-SY5Y | Apoptosis Assay | 10 μM | 24 h | inhibits the neuroprotective effects of hypoxia against PrP (106-126)-mediated neuronal cell death | 23900566 | |
| HKC-8 | Function Assay | 10 µM | 24 h | abolishes β-catenin–mediated RAS induction | 25012166 | |
| HK-2 | Function Assay | 10 µM | 3 h | reduced the expression of TGF-β1, α-SMA, and CTGF after treatment with HHE | 23690997 | |
| HepT1 | Apoptosis Assay | 0-100 μM | 24 h | IC50=34 μM | 23266718 | |
| HuH6 | Apoptosis Assay | 0-100 μM | 24 h | IC50=39 μM | 23266718 | |
| MCF7 | Function Assay | 5 μm | inhibits leptin-mediated increased expression of Snail, Slug, and Zeb2 | 22270359 | ||
| RLE-6TN | Function Assay | 2.5/5/7.5 μM | 48 h | inhibits TGF-β1-induced α-SMA induction and EMT | 22241478 | |
| HKC-8 | Function Assay | 5/10/20 μM | 48 h | blocks β-catenin-driven gene expression | 21816937 | |
| SW480 | Growth Inhibition Assay | 2-100 μM | IC50=5.8±0.68 μM | 15782138 | ||
| SW480 | Function assay | Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis, IC50 = 1.3 μM. | 23232060 | |||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, GI50 = 6.1 μM. | 24950489 | ||
| HepG2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay, GI50 = 12.7 μM. | 24950489 | ||
| LoVo | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay, GI50 = 15.6 μM. | 24950489 | ||
| HT-29 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, GI50 = 17.2 μM. | 24950489 | ||
| HT29 | Function assay | 24 hrs | Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control, IC50 = 18.7 μM. | 24950489 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| LoVo | Cytotoxicity assay | 10 uM | 72 hrs | Cytotoxicity against Wnt/beta-catenin signalling dependent human LoVo cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay | ChEMBL | |
| NCI-H1703 | Function assay | 10 uM | 24 hrs | Inhibition of TNIK in human NCI-H1703 cells transfected with lentiviral vector 7TFP assessed as reduction of GSK3 inhibitor X activated TNIK-mediated Wnt/TCF/beta-catenin-dependent transcription at 10 uM after 24 hrs by luciferase reporter assay | ChEMBL | |
| HCT116 | Cytotoxicity assay | 10 uM | 72 hrs | Cytotoxicity against Wnt/beta-catenin signalling dependent human HCT116 cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay | ChEMBL | |
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 548.63 | Formule | C33H32N4O4 |
Stockage (À compter de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry) | Télécharger le SDF | Stockage des solutions mères |
|
|
|
In vitro |
DMSO
: 30 mg/mL
(54.68 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
CBP
(Cell-free assay) 3 μM
|
|---|---|
| In vitro |
ICG-001 has no effect on the related reporter construct, FOPFLASH, which contains mutated TCF sites. After treatment with 25μM of this compound for 8 hours, SW480 cell reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein, both of which can be up-regulated by β-catenin. This compound selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells. It can phenotypically rescue normal nerve growth factor (NGF) -induced neuronal differentiation and neurite outgrowth in the presenilin-1 mutant cells, emphasizing the importance of the TCF/β-catenin signaling pathway on neurite outgrowth and neuronal differentiation. A recent study demonstrates that 5μM of this chemical inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells. |
| Essai kinase |
Test de rapporteur DUAL-Luciférase
|
|
Le système DUAL-Luciferase Reporter (DLR) Assay System offre un moyen efficace de réaliser des tests de double rapporteur. Dans l'essai DLRTM, les activités des luciférases de luciole (Photinus pyralis) et de Renilla (Renilla reniformis, également connue sous le nom de plume de mer) sont mesurées séquentiellement à partir d'un seul échantillon. Le rapporteur luciférase de luciole est mesuré en premier en ajoutant le réactif de test de luciférase II (LAR II) pour générer un signal luminescent de type « lumière ». Après avoir quantifié la luminescence de la luciole, cette réaction est éteinte et la réaction de la luciférase de Renilla est initiée en ajoutant simultanément le réactif Stop & Glo® dans le même tube. Le réactif Stop & Glo® produit également un signal de type « lumière » de la luciférase de Renilla, qui diminue lentement au cours de la mesure. Dans le système DLRTM Assay, les deux rapporteurs donnent des dosages linéaires avec des sensibilités subattomolaires (<10-18) et aucune activité endogène de l'un ou l'autre des rapporteurs dans les cellules hôtes expérimentales. De plus, le format intégré du DLRTM Assay permet une quantification rapide des deux rapporteurs, soit dans les cellules transfectées, soit dans les réactions de transcription/traduction acellulaires.
|
|
| In vivo |
Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent, which has consistently demonstrated efficacy in this model. No overt toxicity is detected throughout the course of treatment. In the SW620 nude mouse xenograft model of tumor regression, 150 mg/kg, i.v. of this compound demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss. This chemical (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium. |
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | SOX-2 / CD44 / Survivin / EGFR / FOXM1 / EZH2 / Vimentin |